Eric Dube, Travere Therapeutics CEO
FDA punts Travere's rare kidney disease NDA for three months, requesting REMS update
A former Martin Shkreli biotech is at the FDA’s gates for its lead candidate, but it’s going to have to wait a bit longer for …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
